July 20, 2020 04:53 PM EDTUpdated 05:17 PM

Acadia’s shot at beating a ‘fickle’ major depression challenge misses the mark in a failed PhIII

Acadia’s hit-and-miss record with Nuplazid (pimavanserin) has just missed a big Phase III mark by a wide margin.
The biotech $ACAD reports that …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Aca­dia’s shot at beat­ing a ‘fick­le’ ma­jor de­pres­sion chal­lenge miss­es the mark in a failed PhI­II